InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,995.54
(
0.38%
)
US TECH 100
20,628.00
(
0.30%
)
Dow Jones
43,988.99
(
0.59%
)
Brent Oil
73.05
(
-0.90%
)
Bitcoin
81,784.82
(
1.62%
)
Post# of 19309
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120700
Boards Moderated 13
Alias Born 09/05/2002

DewDiligence

Member Level

Re: xrymd post# 12690

Tuesday, 07/08/2008 4:24:12 PM

Tuesday, July 08, 2008 4:24:12 PM

Post# of 19309
CABG/HR is a $100-200M market in the US — very much smaller than the potential market for ATryn in DIC/sepsis.

The reason Ovation prefers CABG/HR for the first acquired-deficiency indication is that they think they can proceed directly to phase-3 based on GTC’s prior CABG/HR studies.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up